Pregnancy and amyloidogenesis: I. Offspring of amyloidotic mice are not predisposed to develop amyloidosis

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 2, 1999, Pages 168-172

  Shtrasburg, Shmuel ^a   Pras, Mordechai ^b   Brezniak, Naphtali ^b   Dolitzki, Mordechai ^b   Livneh, Avi ^b  

^a HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033180454     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90122-1     Document Type: Article

References (28)

1. 1. Cohen AS. Proteins of the systemic amyloidoses, Curr Opin Rheumatol 1994;6:55-67.
2. 2. Gruys E, Snel FWJJ. Animal models for reactive amyloidosis. Bailliere's Clin Rheumatol 1994;8:599-611.
3. 3. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest 1972;51:2773-6.
4. 4. Yakar S, Livneh A, Kaplan B, Pras M. The molecular basis of reactive amyloidosis. Semin Arthritis Rheum 1995;24:255-61.
5. 5. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 1991;70:246-56.
6. 6. Gafni J, Sohar E, Zemer D, Renal involvement in various conditions: amyloid nephropathy. In: Hamburger J, Crosnier J, Grünfeld JP, editors. Nephrology. New-York: Willy; 1979. p. 689-710.
7. 7. Cohen AS, Shirahama T. Animal model: spontaneous and induced amyloidosis. Am J Pathol 1972;68:441-4.
8. 8. Sipe JD, McAdam KPWJ, Uchino F. Biochemical evidence for biphasic development of experimental amyloidosis. Lab Invest 1978;38:110-4.
9. 9. Brandwein SR, Sipe JD, Skinner M, Cohen AS. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation. Lab Invest 1985;52:319-25.
10. 10. Shirahama T, Miura K, Ju S-T, Kisilevsky R, Gruys E, Cohen AS. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest 1990;62:61-8.
11. 11. Baltz ML, Caspi D, Hind CRK, Feinstein A, Pepys MB. Isolation and characterization of amyloid enhancing factor (AEF). In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, Zucker-Franklin D, editors. Amyloidosis. New-York: Plenum Press; 1986. p. 115-21.
12. 12. Shtrasburg S, Livneh A, Gal R, Pras M. Extremely active murine amyloid enhancing factor. Clin Exp Rheumatol 1996;14:37-42.
13. 13. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, Skinner M, Further characterization of amyloid-enhancing factor. Lab Invest 1982;47:139-46.
14. 14. Niewold ThA, Gruys E, Arakawa T, Shirahama T, Kisilevsky R. Recombinant human tumour necrosis factor-α (rhTNF-α) and rhTNF-α analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol 1993;37:29-32.
15. 15. Kisilevsky R, Gruys E, Shirahama T. Does amyloid enhancing factor (AEF) exist? Is AEF a single biological entity? Amyloid Int J Exp Clin Invest 1995;2:128-33.
16. 16. Gonnerman WA, Kandel R, Cathcart ES. Amyloid enhancing factor is produced by rats and amyloid-resistant CE/J mice. Lab Invest 1996;74:259-64.
17. 17. Shirahama T, Abraham CR, Ju S-T, Miura K, Cohen AS. Isolation of a 16 KD fraction with extremely high AEF activity. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, et al, editors. Amyloid and amyloidosis 1990. Dordrecht: Kluwer Academic Publishers; 1990. p. 288-91.
18. 18. Ganowiak K, Hultman P, Engstrom U, Gustavsson A, Westennark P. Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 1994;199:306-12.
19. 19. Niewold ThA, Hol PR, van Andel ACJ, Lutz ETG, Gruys E. Enhancement of amyloid induction by amyloid fibril fragments in hamster. Lab Invest 1987;56:544-9.
20. 20. Shtrasburg S, Pras M, Brezniak N, Livneh A. Long term effects of amyloid enhancing factor: clinical and experimental implications. Clin Exp Rheumatol 1998; 16:299-302.
21. 21. Heller H, Sohar E, Gafni J, Heller J. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch Intern Med 1961; 107:539-50.
22. 22. Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial Mediterranean fever. A population study. Israel J Med Sci 1968;4:995-9.
23. 23. David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993;11:85-90.
24. 24. Feitelson PJ, Ortiz R, Lindheimer MD. Pregnancy and nephrotic syndrome due to renal amyloidosis. Am J Obstet Gynecol 1971;111:306-7.
25. 25. Blumenthal NJ, Levin SL. Amyloidosis and pregnancy. A case report. S Afr Med J 1981;60:552-3.
26. 26. Livneh A, Cabili S, Zemer D, Rabinovitch O, Pras M. Effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. J Rheumatol 1993;20:1519-23.
27. 27. Shtrasburg S, Gal R, Pras M. Crush and smear technique for rapid detection and semiquantitation of amyloid deposition. Biotech Histochem 1991;66:203-7.
28. 28. Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting the outcome. Arthritis Rheum 1994;37:1804-11.